Search clinical trials for: Moderate plaque psoriasis

Total 20212 results

UCB Biopharma SRL

Recruiting

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis (BE TOGETHER)

Moderate to Severe Plaque Psoriasis

United States
Taizhou Mabtech Pharmaceutical Co.,Ltd

Not yet recruiting

Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis

Psoriasis
AbbVie

Recruiting

A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)

Moderate Plaque Psoriasis

United States, Puerto Rico
InventisBio Co., Ltd

Recruiting

Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque Psoriasis

Plaque Psoriasis

China
Bristol-Myers Squibb

Not yet recruiting

Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea

Moderate-to-severe Plaque Psoriasis

Korea, Republic of
AbbVie

Recruiting

Study to Evaluate the Effectiveness of Risankizumab in Participants With a Recent Diagnosis of Moderate Plaque Psoriasis in a Real-life Setting in Greece (REDEFINE)

Psoriasis | Moderate Plaque Psoriasis | Moderate Psoriasis

Greece
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

Plaque Psoriasis

United States, Korea, Republic of, Taiwan, Germany, Poland, Brazil, Spain, Hungary, Australia, Canada, Romania
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

A Clinical Study to Compare the Safety and Pharmacokinetics of SHR-1314 Injection in Healthy Subjects at Different Specifications Devices

Moderate-to-Severe Plaque Psoriasis

China
Eli Lilly and Company

Recruiting

A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Plaque Psoriasis

United States
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

Korea, Republic of, United Kingdom, United States, Poland, Germany, Brazil, Spain, Taiwan, Hungary, Japan, Canada, Argentina, Australia
Novartis Pharmaceuticals

Recruiting

Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis (SPARROW)

Moderate-to-severe Plaque Psoriasis

Russian Federation
Amgen

Recruiting

A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO) (ESSENCE)

Plaque Psoriasis

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis

Moderate to Severe Plaque Psoriasis

China
Takeda

Recruiting

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

Plaque Psoriasis

United States, Canada, Bulgaria, Hungary
Bristol-Myers Squibb

Recruiting

A Study to Evaluate Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis in Germany (DELPHIN) (DELPHIN)

Plaque Psoriasis

Germany
Amgen

Recruiting

A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis

Plaque Psoriasis

United States
Takeda

Recruiting

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

Plaque Psoriasis

United States, Canada, Poland, Italy, Japan
Hansoh BioMedical R&D Company

Recruiting

A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis

Psoriasis

China
Akeso

Recruiting

To Evaluate the Efficacy and Safety of AK111 Injection in the Treatment of Moderate to Severe Plaque Psoriasis

Skin Diseases | Psoriasis

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

IBI112 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment

Psoriasis

China
Janssen Research & Development, LLC

Recruiting

Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM)

Moderate Plaque Psoriasis

United States, Canada
Almirall, S.A.

Recruiting

A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

Austria
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis

Moderate to Severe Chronic Plaque Psoriasis

China
AbbVie

Recruiting

An Observational Study to Validate the Cumulative Life Course Impairment (CLCI) Instrument (DermCLCI-p) in Adult Participants With Moderate to Severe Chronic Plaque Psoriasis (PsO) (IMMagine)

Psoriasis

Canada, Belgium, Germany
First Hospital of China Medical University
China-Japan Friendship Hospital

Not yet recruiting

Real World Study on the Efficacy and Safety of Apremilast in Chinese Patients With Moderate to Severe Plaque Psoriasis, a Multi Center, Prospective, Observational Trial（REACT）

Psoriasis

China
Almirall, S.A.

Recruiting

A Study to Assess Treatment Satisfaction, Patient-reported Outcomes, Effectiveness, and Safety of a Fixed-dose Combination of Calcipotriene/Betamethasone Dipropionate PAD Cream in the Treatment of Mild-to-moderate Plaque Psoriasis of the Scalp in Adults (PRO-SCALP)

Plaque Psoriasis

Germany, Spain, United Kingdom
Hangzhou Highlightll Pharmaceutical Co., Ltd

Recruiting

The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis

Plaque Psoriasis

United States
Artax Biopharma Inc

Recruiting

Proof of Concept Study of AX-158 in Patients With Mild to Moderate Plaque Psoriasis

Psoriasis | Plaque Psoriasis

United Kingdom
SFA Therapeutics

Recruiting

Study of SFA002 in Patients With Mild to Moderate Psoriasis Plaques

Psoriasis

United States
Amgen

Recruiting

A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

Japan
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Recruiting

A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis

Psoriasis

China
Huabo Biopharm Co., Ltd.

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

China
Celltrion

Recruiting

To Compare Pharmacokinetics, Efficacy, and Safety of CT-P17 With Humira in Patients With Moderate to Severe Chronic Plaque Psoriasis

Moderate to Severe Chronic Plaque Psoriasis

Estonia
Soligenix

Recruiting

Topical SGX302 for Mild-to-Moderate Psoriasis

Psoriasis | Plaque Psoriasis | Psoriasis Vulgaris

United States
GC Cell Corporation

Recruiting

Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With Psoriasis

Moderate to Severe Plaque Psoriasis

Korea, Republic of
Centre of Evidence of the French Society of Dermatology

Recruiting

Systemic Treatment of Moderate-to-severe Psoriasis in Adults: Update of the French Guidelines

Psoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Palmaris | Psoriatic Erythroderma | Psoriatic Nail | Psoriasis Guttate | Psoriasis Inverse | Psoriasis Pustular

France
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Efficacy 、Safety and PK of SHR-1314 in Patients With Moderate-to-Severe Plaque Psoriasis

Moderate-to-Severe Plaque Psoriasis
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

Australia, Mexico, Canada, United Kingdom, France, Argentina, Japan, Poland, Spain, Korea, Republic of, Brazil, Germany, Romania
Weill Medical College of Cornell University
Pfizer

Recruiting

Rimegepant in Moderate Plaque-type Psoriasis

Psoriasis

United States
Sun Pharmaceutical Industries Limited

Recruiting

To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis (SOLARES-PsO-1)

Moderate to Severe Plaque Psoriasis

United States, El Salvador
AbbVie

Recruiting

Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyrizi) in Adult Participants With Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis

Psoriasis | Psoriatic Arthritis

Korea, Republic of
LEO Pharma

Recruiting

Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight (ADJUST)

Psoriasis Vulgaris

Belgium, Italy, Spain, Germany, Czechia, Greece, United Kingdom, France, Hungary, Poland, Netherlands
UCB Biopharma SRL

Recruiting

A Study to Evaluate the Efficacy, Safety, and Drug Concentration of Certolizumab Pegol (CZP) in Children and Adolescent Study Participants With Moderate to Severe Chronic Plaque Psoriasis (PSO) (CIMcare)

Moderate Chronic Plaque Psoriasis | Severe Chronic Plaque Psoriasis | Mixed Guttate/Plaque Psoriasis

United States, Canada, Puerto Rico
Sun Pharmaceutical Industries Limited

Recruiting

A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis

Moderate-to-severe Chronic Plaque Psoriasis

United States, Hungary, India, Poland, Slovakia, Spain
Ismart

Not yet recruiting

Safety and Effectiveness of Combined LED Light for the Treatment of Mild to Moderate Plaque Type Psoriasis Vulgaris

Psoriasis Vulgaris
Janssen-Cilag International NV

Recruiting

A Safety Study of Ustekinumab in the Treatment of Pediatric Participants Aged 6 Years and Older With Moderate to Severe Plaque Psoriasis (STELARA)

Psoriasis

Belgium, United Kingdom, Austria, Denmark, France, Germany, Netherlands, Norway, Russian Federation, Switzerland, Greece
Amgen

Terminated

Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

Psoriasis

United States, Belgium, Spain, Czechia, Canada, Italy, Israel, France, Netherlands, Russian Federation
Sun Pharmaceutical Industries Limited

Active, not recruiting

Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis

Chronic Plaque Psoriasis | Moderate to Severe Nail Psoriasis

United States, Australia
Amgen

Completed

Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy (ADVANCE)

Psoriasis

United States, Canada
Janssen-Cilag International NV

Active, not recruiting

A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis (GUIDE)

Psoriasis

Germany, France

3

Subscribe